|
- Home | Insulet
Making a difference Insulet (NASDAQ: PODD), headquartered in Acton, Massachusetts, and with offices and manufacturing facilities around the world, is a global company with growing reach We strive to bring our innovations to all who need them, wherever they are
- About Insulet
Insulet (NASDAQ: PODD) is an innovative medical device company improving the lives of people with diabetes and other conditions through its Omnipod delivery system
- Insulet Corporation - Investor Relations
Insulet Corporation is an innovative medical device company based in Acton, Massachusetts It was founded in 2000 with the mission of improving the lives of people with diabetes
- Insulet Corporation - Insulet’s RADIANT Trial Demonstrates Meaningful . . .
The study found that for adults and children not previously meeting clinical targets for HbA1c on MDI, Insulet’s Omnipod 5 AID System provided clinically significant improvements in HbA1c compared with MDI used with a continuous glucose monitor (CGM)
- Innovation - Insulet
Insulet is committed to improving health outcomes and quality of life for people with diabetes We team up with researchers, healthcare professionals, and centers of excellence worldwide to conduct studies in patients with diabetes of various ages using our devices
- Insulet Corporation - From Injections to Innovation – Insulet to . . .
Insulet’s flagship innovation, the Omnipod 5 Automated Insulin Delivery System, integrates with a continuous glucose monitor to manage blood sugar with no multiple daily injections, zero fingersticks, and can be controlled by a compatible personal smartphone in the U S or by the Omnipod 5 Controller
- Insulet to Share Additional Evidence Demonstrating the Impact of . . .
Insulet will bring immersive booth experiences that showcase how Omnipod 5 is transforming diabetes management Attendees can engage in hands-on demonstrations led by clinical experts, exploring optimization techniques that support better outcomes
- Insulet Corporation - Insulet Reports First Quarter 2025 Revenue . . .
ACTON, Mass -- (BUSINESS WIRE)-- Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced financial results for the three months ended March 31, 2025
|
|
|